Bioventus (BVS) Stock Price, News & Analysis

Company Overview

Bioventus, Inc. (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement. The company also offers a suite of orthobiologic injectables, such as hyaluronic acid–based viscosupplements, to support joint lubrication and pain management in patients with osteoarthritis. In addition, Bioventus provides surgical bone graft substitutes and other regenerative medicine products to assist surgeons in addressing complex bone and soft tissue injuries.

With operations spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East, Bioventus serves hospitals, orthopaedic clinics, and ambulatory surgery centers around the world. The company maintains manufacturing and research facilities in the United States and Europe, and has established distribution partnerships to make its therapies accessible across more than 90 countries. This global footprint enables Bioventus to address diverse patient needs and collaborate closely with healthcare providers in various markets.

Founded in 2012 following a spin-off of Smith & Nephew’s biologics division, Bioventus is headquartered in Durham, North Carolina. Since its inception, the company has pursued a strategy of targeted research and development, strategic acquisitions, and clinical collaborations to expand its product offerings and drive adoption of its technologies. Bioventus is led by an experienced management team committed to innovation, quality, and improving patient care in orthopaedics and musculoskeletal medicine.

Key Stats

• Today's Range: $6.91 to $7.10
• 50-Day Range: $6.14 to $7.64
• 52-Week Range: $5.81 to $14.38
• Volume: 94,476 shs
• Average Volume: 392,908 shs
• Market Capitalization: $575.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.75
• Consensus Rating: Moderate Buy

Bioventus Stock Analysis - MarketRank™

Bioventus scored higher than 59% of companies evaluated by MarketBeat, and ranked 420th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Bioventus has a consensus price target of $13.75, representing about 98.3% upside from its current price of $6.93.

Amount of Analyst Coverage

Bioventus has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 12.20%

Earnings Growth

Earnings for Bioventus are expected to grow by 12.20% in the coming year, from $0.41 to $0.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bioventus is -11.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bioventus is -11.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bioventus has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BVS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bioventus does not currently pay a dividend.

Dividend Growth

Bioventus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BVS.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.34

News Sentiment

Bioventus has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bioventus this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Bioventus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bioventus insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.00% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BVS Stock Analysis - Frequently Asked Questions

How have BVS shares performed this year?

Bioventus' stock was trading at $10.50 at the beginning of the year. Since then, BVS shares have decreased by 34.0% and is now trading at $6.9340.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) issued its quarterly earnings results on Tuesday, November, 5th. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The company had revenue of $138.96 million for the quarter, compared to the consensus estimate of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 15.61%.

When did Bioventus IPO?

Bioventus (BVS) raised $126 million in an initial public offering (IPO) on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

Who are Bioventus' major shareholders?

Bioventus' top institutional investors include Nantahala Capital Management LLC (6.43%), American Century Companies Inc. (1.37%), Divisadero Street Capital Management LP (1.32%) and Geode Capital Management LLC (1.28%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, Mark Leonard Singleton, William A Hawkins, Anthony P Bihl III, Anthony D'adamio, John Nosenzo, Robert E Claypoole, Katrina J Church and Kenneth Michael Reali.
View institutional ownership trends.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bioventus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), ServiceNow (NOW), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 9/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:BVS
• CIK: 1665988
• Web: www.bioventus.com
• Phone: 919-474-6700
• Fax: N/A
• Employees: 1,200
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Bioventus: $13.75
• High Price Target: $15.00
• Low Price Target: $12.00
• Potential Upside/Downside: +98.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 16.93
• P/E Growth: N/A
• Net Income: -$156.23 million
• Net Margins: -7.11%
• Pretax Margin: -10.41%
• Return on Equity: 15.61%
• Return on Assets: 4.01%

Debt

• Debt-to-Equity Ratio: 1.85
• Current Ratio: 1.41
• Quick Ratio: 0.99

Sales & Book Value

• Annual Sales: $564.14 million
• Price / Sales: 1.02
• Cash Flow: $0.55 per share
• Price / Cash Flow: 12.58
• Book Value: $2.80 per share
• Price / Book: 2.48

Miscellaneous

• Outstanding Shares: 82,679,000
• Free Float: 54,455,000
• Market Cap: $573.79 million
• Optionable: Not Optionable
• Beta: 0.84